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Abstract Pulsed-mode ultrasound (pUS) in combination
with intravenously (IV) administered microbubbles (MBs)
can enhance local drug delivery by temporarily enhancing
capillary permeability. This study evaluates the use of
epidermal growth factor receptor (EGFR)-targeting MBs
after pUS treatment to enhance the effects of therapeutic-
EGFR antibody delivery to glioma tumor cells in mice.
Three animal groups were compared: (1) IV-injected non-
targeting MBs, (2) IV-injected targeting MBs, and (3) IV-
injected targeting MBs combined with pUS treatment. All
animals were analyzed using high-frequency small-animal
US imaging. The mean halftime of circulating targeting
MBs was significantly increased from 3.13 min of target-
ing bubble alone to 5.86 min by targeting MBs combined
with pUS treatment, compared to 2.34 min for non-tar-
geting MBs. Compared to targeting bubble administration
alone, pUS exposure prior to injection of targeting MBs
was also significantly better at suppressing tumor growth
when monitored for up to 35 days (p\ 0.05). The final
relative tumor volumes were 2664, 700, and 188 mm3 for
non-targeting MBs, targeting MBs, and targeting MBs
combined with pUS treatment, respectively. pUS treatment
prolonged the mean circulatory halftime of targeting MBs
and enhanced the anti-tumor effect of EGFR antibodies in a
human glioma model in mice. Targeting MBs combined
with pUS treatment thus has potential for enhanced
therapeutic antibody delivery for facilitating anti-glioma
treatment.
Keywords Microbubbles  Epidermal growth factor
receptor  Pulsed ultrasound
1 Introduction
Epidermal growth factor receptor (EGFR) is a single
transmembrane receptor tyrosine kinase. The binding of a
ligand, such as epidermal growth factor (EGF) or trans-
forming growth factor-a (TGF-a), to the extracellular do-
main of EGFR induces its conformational change,
dimerization, and trans-phosphorylation of specific recep-
tor tyrosine residues. These phosphorylated-tyrosine resi-
dues generate docking sites for downstream signaling
molecules, leading to the activation of phosphoinositide 3
kinase/AKT, mitogen-activated protein (MAP) kinase, and
JNK-STATs pathways. These signaling activities promote
cell proliferation, mobility, and anti-apoptosis [1, 2]. The
mechanisms involved in the activation of EGFR include
receptor overexpression [3], autocrine activation by over-
production of ligands [4], ligand-independent activation
through other receptor systems and mutant receptors re-
sulting in ligand-independent activation [5]. Preclinical and
clinical studies have validated the targeting of EGFR as an
anticancer therapy. Four treatment strategies that involve
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the targeting of EGFR and the blocking of its downstream
signaling pathways have been developed: monoclonal an-
tibodies directed against the extracellular domain of EGFR;
small molecules for intracellular blocking of tyrosine-
kinase activation (tyrosine-kinase inhibitors, TKIs); an-
tisense oligonucleotides to inhibit EGFR synthesis; and
antibody-based immunoconjugates such as immunotoxins
or immunoliposomes for specific and efficient delivery of
anticancer agents to EGFR-overexpressing tumors [6].
Malignant gliomas constitute the most common primary
brain tumors in adults and rank among the most devastating
and aggressive types of human cancer due to their dismal
prognosis. A number of genetic alterations are responsible
for the malignancy of these tumors, and mutations leading
to the hyperactivation of receptor tyrosine kinases are
common. EGFR is often overexpressed and amplified in
gliomas, and contributes to uncontrolled proliferation and
survival of glioma cells [7]. EGFR inhibition is effective in
the reduction of the proliferation, motility, and invasion of
cells expressing wild-type, mutant, or amplified EGFR [3].
Pulsed-mode ultrasound (pUS) exposure therapy was re-
cently shown to enhance the anti-tumor effect of an EGFR-
targeting chemotherapeutic drug in colon-cancer-bearing
mice [8]. pUS shows great potential for the targeted delivery
of therapeutic agents, including chemotherapeutic drugs,
nanoparticles, and genes, to tumors [9]. Gas-filled echogenic
microbubbles (MBs) are applied as a clinical contrast agent
to enhance vascular information in US imaging. pUS-en-
hanced local brain drug delivery also relies on the intra-
venous (IV) administration of MBs and interaction with
ultrasonic energy for the temporary disruption of the lumen
and endothelial cell junction to enhance permeability of
tissues to circulating drugs. pUS in the presence of MBs
(pUS-MBs) is a noninvasive technique that shows great
promise for local and reversible enhancement of the per-
meability of central nervous system (CNS) capillaries (so-
called blood–brain barrier disruption) to enhance
chemotherapeutic agent delivery in malignant glioma ap-
plications [10]. Imaging the tumor vasculature can be
clinically useful for both the diagnosis and monitoring of
tumor responses to antiangiogenic therapy. MBs have also
been used as drug carriers and thus provide the potential to
combine US imaging with pUS-mediated therapy [11, 12].
EGFR therapeutic antibodies such as cetuximab and
panitumumab can inhibit the binding of ligands to EGFR and
suppress EGFR signaling, and have been approved by the
FDA for the treatment of head and neck cancer and
metastatic colorectal cancer [13]. Cetuximab induces inter-
nalization of the antibody-receptor complex leading to
down-regulation of EGFR expression. Furthermore, the Fc
region of the antibodymay recruit and activate immune cells
or complement to induce antibody-dependent cell-mediated
cytotoxicity or complement-dependent cytotoxicity [14].
Pre-clinical studies have also shown that cetuximab treat-
ment can promote radiation-induced apoptosis and inhibit
tumor angiogensis [15].
The present study evaluates the potential of pUS expo-
sure combined with therapeutic EGFR-targeting MB ad-
ministration for glioma treatment (concepts shown in
Fig. 1). It is hypothesized that pUS-MB exposure can en-
hance blood-tumor permeability and prolong the circula-
tion of the targeting MBs and enhance the local
concentration of therapeutic EGFR delivery at the local
tumor site to provide therapeutic efficacy.
2 Materials and Methods
2.1 Human Primary Glioblastoma Animal Model
U87 glioma cells were cultured at 37 C in an incubator
containing 5 % CO2 in humidified air. Tumor cells were
harvested for culture or injection by washing the monolayer
with phosphate-buffered saline (PBS), followed by a brief
incubation in 0.25 % trypsin and 0.02 % ethylenediaminete-
traacetic acid (EDTA) to detach the cells. After removal of the
trypsin and EDTA, 0.1 ml of cell suspension containing
1 9 106 tumor cells in PBS was injected via a 27-gauge
needle into the hypoderm of the right-lower limbs of male
BALB/c nude mice (Bio-LASCO, Taipei, Taiwan). All ani-
mal experiments were performed according to an animal care
protocol approved by the National Animal Center of Taiwan.
All mice were maintained according to the regulations of
Chang Gung University’s Institutional Animal Care and Use
Committee. BALB/c nudemicewere raised in a roomwith the
thermostat set to 26 C. Mice were 5–6 weeks old and
weighed 25–30 g. Tumor size was measured every 4 days
after tumor implantation until the diameter of the tumor
reached about 8 mm or could be firmly fixed for monitoring.
2.2 Preparation of MBs
TargestarTM-SA (Targeson, La Jolla, CA, USA) MBs were
used in this study to serve as the non-targeting MBs as well
as the US contrast agent to evaluate image intensity.
TargestarTM-SA MBs were suspended in aqueous saline at
a concentration of approximately 1 9 109 particles/ml, and
had a median diameter of approximately 2.5 lm. Targes-
tarTM-SA MBs conjugated with EGFR antibody (Thermo
Fisher Scientific Anatomical Pathology, CA, USA) by bi-
otin-streptavidin conjugation was used for either US
imaging or therapy and served as the targeting MBs. The
conjugated monoclonal antibodies can block the EGF- and
TGFa-induced activation of EGFR (but have no effect on
tyrosine kinase activity of receptor I) and have been con-
firmed to block tumor growth in vivo [16–18].
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2.3 In Vivo High-Frequency US Imaging of MBs
A previous study demonstrated the usefulness of using high-
frequency US to monitor tumor perfusion and micro-envi-
ronmental changes [19]. U87-tumor-bearing male BALB/c
nudemice (n = 6 in each group)were kept anesthetizedwith
2 % isoflurane in oxygen at 2 l/min on a scanning stage. The
hair on the skin over the tumor was clipped, and acoustic gel
was applied to the tumor. A commercial small-animal US
imaging system (Vevo 2100, VisualSonics, Toronto,
Canada) was used. The array transducer had a central fre-
quency of 18 MHz, with axial and lateral resolutions of 75
and 165 lm, respectively. The focal length was 8 mm with
mechanical index (MI) = 0.2. Real-time imaging was per-
formed at a frame rate of 10 Hz (corresponding to a temporal
resolution of 100 ms). Two-dimensional B-mode image
planes were acquired with optimization of the gain and the
time-gain compensation settings, which were kept constant
throughout the experiments. High-frequency US imaging
was applied to the entire tumor of each mouse. After a ra-
diologist identified the tumor lesions, about 1 9 108 MBs
(about 0.1 ml) were injected through the lateral tail vein and
post-contrast-injection US imaging of the tumor lesions was
immediately performed for 20 min.
The regions of interest (ROIs) were drawn over the
whole tumor in a two-dimensional imaging plane by a ra-
diologist, and the average pre- and post-contrast image
intensities were measured in B-mode images. The images
were stored digitally on a built-in hard drive for off-line
analysis of the time-intensity relationship among the
selected ROIs from the acquired image sections. The time-
intensity curves (TICs) were then fitted using a least-
squares algorithm based on the Nelder-Mead method
(Matlab fminsearch function, Matlab, The MathWorks Inc.,
Natick, MA). Several parameters were derived from the
TICs (Fig. 2): peak intensity (PI) was defined as the
maximal intensity; time of peak intensity (TP) was the time
required for the intensity to rise from the base to the peak
corresponding to the MB injection time; half time (HT)
was the time required for the intensity to decrease from the
top to half of the maximum intensity; descending slope
(DS) was the slope of a line between two specific points,
i.e., 85 and 35 % of the peak intensity; peak width (PW)
was the duration between of signal intensity maintaining
higher than 85 % of peak intensity. Two points of 85 % of
peak intensity, before and after the peak point; and area
under the curve (AUC) was the summed area between the
intensity curve and the time axis. Here AUC is in direct
proportion to the amount of MBs present in the tumor.
2.4 In Vivo Therapy by pUS and EGFR Antibody
Delivery
Animals were anesthetized with isofluorane (2.5–3 %
volume with oxygen). The animal was placed on the
acrylic holder and the skin flanking the tumor was fastened
and fixed by stainless clips. The top of the tumor was at-
tached to the bottom of a filled water tank, which had a
50 9 50 mm2 opening. This opening was sealed with an
acoustic-energy-permeable membrane and a 3-mm-thick
Fig. 1 Conceptual diagram of
this study. pUS beam was
focused on glioma tumor. After
injection of targeting MBs, US
imaging was performed
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gelatin pad to insure perfect coupling with no intervening
gas. During sonication, mice were immobilized above the
water tank with their tumor tightly attached to the thin-film
window. The non-targeting US contrast agents were IV
injected into the mice to facilitate acoustic cavitation. Since
a wide sonication area is also helpful for increasing the
permeability of tumor vessels, the focal zone of FUS was
sequentially moved over the entire surface attached to the
thin-film window, with the focus located 3 mm under the
surface of the tumor.
A US transducer (focused type; diameter 60 mm; fre-
quency 400 kHz) driven by the signal generated from an
arbitrary function generator (33220A, Agilent, CA, USA)
was used to enhance the permeability of tumor blood
vessels. The FUS excitation signal was amplified by a ra-
dio-frequency power amplifier (150A100B, Amplifier Re-
search) and monitored by a power-meter (Model 4421,
Bird) before being fed into the US transducer.
pUS exposure (power 5 W; burst length 100 ms; pulse
repetition frequency 1 Hz, sonication duration 20 s per
exposure) in the presence of non-targeting MBs (mixed
with 0.2 ml of saline, followed by flushing with 0.2 ml of
heparin) was employed to enhance vascular permeability
based on previous experiments on small animals [20–22].
Animals typically underwent 9–12 pUS exposures to allow
coverage of the entire tumor region (range of total exposure
time 180–240 s). Since the focal dimension was measured
as approximately 3 mm along the radial direction, the
spacing between individual adjacent focal positions was set
at 3 mm.
The tumor-bearing mice were divided randomly into
three groups (n = 6 in each group): (1) IV-injected non-
targeting TargestarTM-SAMBs; (2) IV-injected targeting
TargestarTM-SA MBs; and (3) pUS exposure prior to IV
injection of targeting TargestarTM-SA MBs. Animals were
treated on a daily basis with targeting TargestarTM-SA
MBs or pUS. During the experimental period of 35 days,
tumor volumes were measured twice a week for growth
curve measurements. At the end of the 35-day intervention,
the mice were sacrificed and tumors were removed, rinsed
in cold saline, and then patted between paper towels. A
portion of each tumor was excised and fixed in 10 %
paraformaldehyde overnight at room temperature. The tu-
mor samples were embedded in paraffin for further im-
munohistochemical analysis. Detailed experimental
designs are shown in Fig. 3.
2.5 Estimation and Comparison of Tumor Growth
Vernier caliper measurements were made before and after
treatment, in which the lengths of the three directions of the
tumor and the tumor volume were calculated according to
the ellipsoid model [21]. The doubling time is the period of
time required for a quantity to double in size or value.
Tumor doubling time was adopted as a factor to estimate
tumor growth. The doubling time (T) of tumor cells in vivo
was calculated as:
T ¼ ðt  t0Þ  log 2
log N  log N0 ð1Þ
where t is a time point during the exponential phase, N is
the tumor volume at time t, and N0 is the tumor volume at
initial time point t0 [23].
2.6 Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue samples from the
surgically resected U87 tumor were cut into 4-mm sections.
Sections were deparaffinized, blocked with 3 % H2O2 in
methanol at 4 C for 20 min, and rinsed with PBS. Sec-
tions were then blocked with normal goat serum for 30 min
to increase the specificity of the primary antibody, and
rinsed with PBS. Streptavidin peroxidase (Cat. No. TS-
060-HR, Thermo Scientific) reagent was used as the pri-
mary antibody to estimate the delivery of injected biotin-
modified therapeutic EGFR antibody. After blocking, the
section was incubated overnight with 100-fold diluted
primary antibody and rinsed with PBS. The directions of
the Polymer-HRP IHC Detection System (QD420-YIK,
BioGenex) were followed. Slides were then counterstained
with hematoxylin and topped with a cover slip. Sections
were also prepared for light microscopy by staining with
hematoxylin and eosin (HE; Sigma-Aldrich, MO, USA) to
assess overall tissue morphology and regional cell viability.
2.7 Statistical Analysis
Data were analyzed statistically using Student’s t test. A
probability value of p\ 0.05 was considered statistically
significant.
Fig. 2 Schematic diagram of parameters for time intensity curve
analysis (top). I(t) denotes intensity
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3 Results
3.1 In Vivo High-Frequency Ultrasound Glioma
Tumor Imaging
B-mode US images showed similar intensities before (pre-
contrast) and after injection of MBs (Fig. 4a, c). However,
the image intensity in nonlinear contrast mode was sig-
nificantly higher after MB injection compared to that in
pre-contrast images (Fig. 4b, d). Therefore, nonlinear
contrast mode US imaging was used to investigate the
accumulation of non-targeting MBs, targeting MBs, and
targeting MBs combined with pUS treatment (Fig. 5).
Image enhancement was lower in pre-contrast images
(Fig. 5, column denoted as ‘‘pre’’) compared to that in
images of injected targeting or non-targeting MBs (Fig. 5,
column denoted as ‘‘0’’). Ten min after MB injection,
image enhancement was still obvious for targeting MBs
and targeting MBs with pUS treatment compared to that of
non-targeting MBs. TICs were acquired for 20 min (Fig. 6)
and used to calculate perfusion parameters (Table 1). The
ratios of the perfusion parameters of the targeting and pUS-
treated groups relative to that of the non-targeted MB
group are shown in Table 2. The PI of non-targeting MBs
was higher than those of the other two groups. However,
the TP, HT, PW, and AUC values of targeting MBs with
pUS treatment were higher than those of the other two
groups. Thus, increased vascular permeability was ob-
served for targeting MBs with pUS treatment. The DS of
targeting MBs with pUS treatment was more moderate
compared to those of the other two groups.
3.2 In Vivo FUS Exposure with Therapeutic EGFR
Antibody Delivery
To evaluate the suppression of EGFR activity by EGFR
antibody, tumor growth was observed for 35 days in the
Fig. 3 Experimental design and protocol (bottom). *only in group 3 animals; **non-targeting MBs were employed in group 1 animals, and
targeting MBs were employed in group 2 and 3 animals
Fig. 4 B-mode tumor images a before (pre-contrast) and c after IV
injection of MBs. Nonlinear contrast mode tumor images b before and
d after IV injection of MBs
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glioma-bearing mice. The growth curves and growth rates of
U87 tumors for various treatments are shown in Figs. 7 and
8, respectively. Treatment with targeting MBs or targeting
MBs after pUS treatment significantly reduced the growth of
established U87 tumors. The final relative tumor volumes
were 2,663.9 ± 2,058.3, 700.0 ± 557.9, and 188.4 ±
184.0 mm3 for non-targeting MBs, targeting MBs, and tar-
geting MBs combined with pUS treatment, respectively
(p value calculated by tumor volume: PTargeting MBs =
0.0737 and PTargeting MBs with pUS = 0.0226. p value calcu-
lated by tumor growth percentage: PTargeting MBs = 0.2304
andPTargeting MBs with pUS = 0.0267). These are equivalent to
38.2 and 209.8 % decreases in tumor doubling time and tu-
mor volume, respectively, compared with those of control
animals (Figs. 7 and 8). These results show that EGFR-tar-
geting MBs injected after pUS treatment are sufficient for
control of U87 tumors, presumably mediated by binding and
inhibition of EGFR by EGFR antibody.
Fig. 5 Contrast-enhanced US images of non-targeting MBs (top row), targeting MBs (middle row), and targeting MBs combined with pUS
treatment (bottom row) at various times
Fig. 6 Typical TIC analysis of IV-injected non-targeting MBs, IV-
injected targeting MBs, and IV-injected targeting MBs combined with
pUS treatment
Table 1 Time intensity curve
analysis using perfusion
parameters
Non-targeting MBs Targeting MBs Targeting MBs ? pUS
PI 109.10 99.17 93.38
TP (min) 0.34 0.73 2.69
HT (min) 2.34 3.13 5.86
DS -18.72 -17.42 -8.46
PW (min) 1.79 1.59 2.679
AUC 5,380.34 5,855.83 10,340.49
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3.3 Immunohistochemistry
EGFR antibody delivery by various treatments was
evaluated by immunohistochemistry at 35 days (Fig. 9a–c).
Sections were also stained with HE (Fig. 9d–f). EGFR an-
tibody was not observed in the control group (Fig. 9a).
Targeting MBs in the absence of pUS treatment resulted in
high levels of EGFR antibody deposition, located mostly
inside vessels. In the targetedMBwith pUS treatment group,
EGFR antibody leaked outside vessels and spread through
tumor tissues (Fig. 9c). pUS treatment clearly enhanced drug
delivery (Fig. 9b versus Fig. 9c), without major histological
changes (HE stain; Fig. 9e versus Fig. 9f).
4 Discussion
This study demonstrated the use of EGFR-targeting MBs
combined with pUS exposure to enhance therapeutic EGFR
antibody delivery to glioma tumor cells in mice. It was
shown that pUS exposure increased the penetration and
circulating half-life of targeting MBs. pUS exposure prior
to injection of targeting MBs also led to a significantly
better tumor suppressing effect. pUS exposure with MBs
thus has potential for enhanced therapeutic antibody de-
livery for facilitating anti-glioma treatment.
Contrast-enhanced ultrasound (CEUS) has been widely
used in the diagnosis of diseases of the heart, liver,
kidney, pancreas, and peripheral vessels [24]. In this
study, the potential of MB-facilitated pUS to enhance the
delivery of therapeutic EGFR antibodies so that the
process can be concurrently monitored by CEUS. Im-
proved spatial resolution of nonlinear contrast imaging
has been demonstrated previously [25]. The nonlinear
contrast imaging mode on a micro-US system can be
used to obtain parametric images to map various pa-
rameters related to blood flow in perfused tumors, with
improved image contrast after the injection of MBs [26].
Such images were used here to generate TICs and de-
termine values for various parameters (Tables 1 and 2).
The TP, HT, and AUC values of non-targeting MBs
were lower than those of both targeting MBs and tar-
geting MBs with pUS. However, the PW of targeting
MBs was lower than that of non-targeting MBs and
targeting MBs with pUS. This result demonstrates the
different perfusion characteristics of targeting MBs and
targeting MBs with pUS. The image intensity for tar-
geting MBs with pUS treatment exhibited a diffuse peak
in the range of 3-6 min, remaining high until 10 min
(Fig. 6). The shift of the TIC distribution in targeting
MBs with pUS treatment indicate an increase in the
lifetime of targeting MBs in the tumor and more tar-
geting MBs delivered into the tumor.
Fig. 7 Tumor volume growth curves for treatment with non-targeting
MBs, targeting MBs, and targeting MBs combined with pUS
treatment. Targeting MBs after pUS treatment showed statistically
significant growth suppression compared to all other groups
(p\ 0.05). Tumor growth of targeting MB treatment group was
mildly suppressed compared to that of non-targeting MBs, but this
difference was still statistically significant (p\ 0.05)
Fig. 8 Tumor volume growth rates for treatment with non-targeting
MBs, targeting MBs, and targeting MBs combined with pUS
treatment
Table 2 Time intensity curve analysis using perfusion parameter
ratios with respect to non-targeting MB group
Targeting MBs Targeting MBs ? pUS
PI 0.91 0.86
TP (min) 2.13 7.81
HT (min) 1.33 2.50
DS 0.93 0.45
PW (min) 0.88 1.49
AUC 1.08 1.92
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EGFR therapy has focused mainly on blocking signal
transduction with monoclonal antibodies. Many anti-EGFR
monoclonal antibodies have been approved by the FDA for
clinical treatment of head and neck cancer and colorectal
cancer. However, all conventional small-molecule drugs or
monoclonal antibodies are quickly metabolized and cleared
through the kidneys, thus requiring high therapeutic con-
centrations, which in turn causes cardiotoxicity or other
toxic side effects [24]. The present study shows that pUS
treatment combined with therapeutic anti-EGFR antibodies
enhances the anti-tumor effect in glioma-bearing mice.
Although tumor growth was inhibited with targeting MB
treatment in the absence of pUS, significant tumor growth
suppression was observed with targeted MBs combined
with pUS, mainly later after 7 days post treatment. More-
over, the tumors did not re-grow in the next 10 days,
perhaps due to an enhanced anticancer effect by mi-
crovascular disruption caused by pUS exposure [22] and
anti-EGFR monoclonal antibody treatment.
No immunological signal for EGFR antibody was ob-
served in the control group in 35-day tumors. However,
anti-EGFR monoclonal antibodies were detected within the
tumor vessels in the targeting MB group, and in both tumor
vessels and tissue in the targeting MB combined with pUS
group. This treatment group showed both inhibition of
EGFR-dependent glioma-cell growth and a large number
of anti-EGFR monoclonal antibodies.
5 Conclusion
In this study, the halftime of targeting MBs in glioma tumor
was prolonged in glioma-bearing mice. Anti-EGFR therapy
with targeting MBs inhibited the growth rate of glioma in
BALB/c nude mice. pUS-mediated MB treatment increased
tumor vessel permeability, thus increasing delivery of tar-
geting MBs and significantly enhancing anti-EGFR therapy
in the tumor. These results demonstrate the feasibility of tu-
mor immunotherapywith targetingMBs combinedwith pUS.
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